|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HSF1 |
Gene summary for HSF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HSF1 | Gene ID | 3297 |
| Gene name | heat shock transcription factor 1 | |
| Gene Alias | HSTF1 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q00613 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3297 | HSF1 | P17T-E | Human | Esophagus | ESCC | 6.66e-22 | 1.03e+00 | 0.1278 |
| 3297 | HSF1 | P19T-E | Human | Esophagus | ESCC | 1.46e-22 | 1.11e+00 | 0.1662 |
| 3297 | HSF1 | P20T-E | Human | Esophagus | ESCC | 8.74e-52 | 1.11e+00 | 0.1124 |
| 3297 | HSF1 | P21T-E | Human | Esophagus | ESCC | 1.53e-91 | 1.82e+00 | 0.1617 |
| 3297 | HSF1 | P22T-E | Human | Esophagus | ESCC | 5.39e-49 | 7.60e-01 | 0.1236 |
| 3297 | HSF1 | P23T-E | Human | Esophagus | ESCC | 4.85e-72 | 1.70e+00 | 0.108 |
| 3297 | HSF1 | P24T-E | Human | Esophagus | ESCC | 6.90e-58 | 1.07e+00 | 0.1287 |
| 3297 | HSF1 | P26T-E | Human | Esophagus | ESCC | 4.86e-103 | 1.66e+00 | 0.1276 |
| 3297 | HSF1 | P27T-E | Human | Esophagus | ESCC | 8.35e-83 | 1.26e+00 | 0.1055 |
| 3297 | HSF1 | P28T-E | Human | Esophagus | ESCC | 3.81e-60 | 1.06e+00 | 0.1149 |
| 3297 | HSF1 | P30T-E | Human | Esophagus | ESCC | 2.49e-41 | 1.56e+00 | 0.137 |
| 3297 | HSF1 | P31T-E | Human | Esophagus | ESCC | 3.13e-80 | 1.41e+00 | 0.1251 |
| 3297 | HSF1 | P32T-E | Human | Esophagus | ESCC | 5.28e-67 | 1.39e+00 | 0.1666 |
| 3297 | HSF1 | P36T-E | Human | Esophagus | ESCC | 6.03e-32 | 1.16e+00 | 0.1187 |
| 3297 | HSF1 | P37T-E | Human | Esophagus | ESCC | 7.04e-38 | 8.75e-01 | 0.1371 |
| 3297 | HSF1 | P38T-E | Human | Esophagus | ESCC | 5.28e-23 | 1.32e+00 | 0.127 |
| 3297 | HSF1 | P39T-E | Human | Esophagus | ESCC | 5.89e-49 | 8.91e-01 | 0.0894 |
| 3297 | HSF1 | P40T-E | Human | Esophagus | ESCC | 8.71e-25 | 8.49e-01 | 0.109 |
| 3297 | HSF1 | P42T-E | Human | Esophagus | ESCC | 2.18e-33 | 1.04e+00 | 0.1175 |
| 3297 | HSF1 | P44T-E | Human | Esophagus | ESCC | 1.07e-18 | 5.90e-01 | 0.1096 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190331120 | Esophagus | HGIN | regulation of mRNA metabolic process | 91/2587 | 288/18723 | 5.06e-15 | 9.78e-13 | 91 |
| GO:005068419 | Esophagus | HGIN | regulation of mRNA processing | 55/2587 | 137/18723 | 2.17e-14 | 3.94e-12 | 55 |
| GO:004586227 | Esophagus | HGIN | positive regulation of proteolysis | 107/2587 | 372/18723 | 2.61e-14 | 4.60e-12 | 107 |
| GO:000989626 | Esophagus | HGIN | positive regulation of catabolic process | 126/2587 | 492/18723 | 1.46e-12 | 2.09e-10 | 126 |
| GO:000640320 | Esophagus | HGIN | RNA localization | 66/2587 | 201/18723 | 4.06e-12 | 5.41e-10 | 66 |
| GO:003133126 | Esophagus | HGIN | positive regulation of cellular catabolic process | 112/2587 | 427/18723 | 5.15e-12 | 6.72e-10 | 112 |
| GO:003596625 | Esophagus | HGIN | response to topologically incorrect protein | 54/2587 | 159/18723 | 8.53e-11 | 8.89e-09 | 54 |
| GO:000698625 | Esophagus | HGIN | response to unfolded protein | 48/2587 | 137/18723 | 2.80e-10 | 2.54e-08 | 48 |
| GO:003460520 | Esophagus | HGIN | cellular response to heat | 30/2587 | 69/18723 | 1.78e-09 | 1.35e-07 | 30 |
| GO:000697927 | Esophagus | HGIN | response to oxidative stress | 107/2587 | 446/18723 | 3.91e-09 | 2.76e-07 | 107 |
| GO:003596725 | Esophagus | HGIN | cellular response to topologically incorrect protein | 41/2587 | 116/18723 | 4.07e-09 | 2.84e-07 | 41 |
| GO:003462020 | Esophagus | HGIN | cellular response to unfolded protein | 36/2587 | 96/18723 | 5.82e-09 | 3.88e-07 | 36 |
| GO:003465519 | Esophagus | HGIN | nucleobase-containing compound catabolic process | 98/2587 | 407/18723 | 1.44e-08 | 8.94e-07 | 98 |
| GO:004328126 | Esophagus | HGIN | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 59/2587 | 209/18723 | 3.39e-08 | 1.97e-06 | 59 |
| GO:004670017 | Esophagus | HGIN | heterocycle catabolic process | 103/2587 | 445/18723 | 5.44e-08 | 2.99e-06 | 103 |
| GO:005065716 | Esophagus | HGIN | nucleic acid transport | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
| GO:005065816 | Esophagus | HGIN | RNA transport | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:200011626 | Esophagus | HGIN | regulation of cysteine-type endopeptidase activity | 63/2587 | 235/18723 | 9.71e-08 | 5.02e-06 | 63 |
| GO:005123616 | Esophagus | HGIN | establishment of RNA localization | 49/2587 | 166/18723 | 1.07e-07 | 5.47e-06 | 49 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513427 | Esophagus | HGIN | Legionellosis | 18/1383 | 57/8465 | 3.20e-03 | 2.54e-02 | 2.02e-02 | 18 |
| hsa05134112 | Esophagus | HGIN | Legionellosis | 18/1383 | 57/8465 | 3.20e-03 | 2.54e-02 | 2.02e-02 | 18 |
| hsa0513428 | Esophagus | ESCC | Legionellosis | 42/4205 | 57/8465 | 1.83e-04 | 6.90e-04 | 3.53e-04 | 42 |
| hsa0513436 | Esophagus | ESCC | Legionellosis | 42/4205 | 57/8465 | 1.83e-04 | 6.90e-04 | 3.53e-04 | 42 |
| hsa0513412 | Liver | Cirrhotic | Legionellosis | 28/2530 | 57/8465 | 1.71e-03 | 8.01e-03 | 4.94e-03 | 28 |
| hsa0513413 | Liver | Cirrhotic | Legionellosis | 28/2530 | 57/8465 | 1.71e-03 | 8.01e-03 | 4.94e-03 | 28 |
| hsa0513425 | Oral cavity | OSCC | Legionellosis | 42/3704 | 57/8465 | 4.18e-06 | 2.15e-05 | 1.10e-05 | 42 |
| hsa05134111 | Oral cavity | OSCC | Legionellosis | 42/3704 | 57/8465 | 4.18e-06 | 2.15e-05 | 1.10e-05 | 42 |
| hsa0513426 | Oral cavity | LP | Legionellosis | 33/2418 | 57/8465 | 3.29e-06 | 3.23e-05 | 2.08e-05 | 33 |
| hsa0513435 | Oral cavity | LP | Legionellosis | 33/2418 | 57/8465 | 3.29e-06 | 3.23e-05 | 2.08e-05 | 33 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| HSF1 | PERI | Lung | ADJ | CCDC36,TTPAL,ARHGEF37, etc. | 5.45e-03 |  |
| HSF1 | ICAF | Lung | ADJ | CCDC36,TTPAL,ARHGEF37, etc. | 0.00e+00 | |
| HSF1 | ADIPO | Lung | Healthy | CCDC36,TTPAL,ARHGEF37, etc. | 4.40e-03 |  |
| HSF1 | MYOFIB | Lung | Healthy | CCDC36,TTPAL,ARHGEF37, etc. | 2.22e-16 | |
| HSF1 | GRA | Oral cavity | NEOLP | GRINA,SNX3,CD164, etc. | 1.18e-02 |  |
| HSF1 | NUER | Prostate | ADJ | IP6K2,TBX19,WWP2, etc. | 4.00e-02 |  |
| HSF1 | BAS | Prostate | ADJ | IP6K2,TBX19,WWP2, etc. | 2.34e-02 | |
| HSF1 | BAS | Prostate | BPH | IP6K2,TBX19,WWP2, etc. | 2.26e-01 |  |
| HSF1 | BAS | Prostate | Tumor | IP6K2,TBX19,WWP2, etc. | 4.87e-02 |  |
| HSF1 | NKT | Prostate | BPH | TCAIM,KRT17,CLTB, etc. | 1.32e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HSF1 | SNV | Missense_Mutation | c.1477N>A | p.Glu493Lys | p.E493K | Q00613 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| HSF1 | SNV | Missense_Mutation | rs781942523 | c.526N>T | p.Arg176Trp | p.R176W | Q00613 | protein_coding | deleterious(0.01) | benign(0.063) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HSF1 | SNV | Missense_Mutation | rs781942523 | c.526C>T | p.Arg176Trp | p.R176W | Q00613 | protein_coding | deleterious(0.01) | benign(0.063) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| HSF1 | SNV | Missense_Mutation | c.606N>G | p.Ile202Met | p.I202M | Q00613 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| HSF1 | SNV | Missense_Mutation | c.141C>G | p.Phe47Leu | p.F47L | Q00613 | protein_coding | tolerated(0.14) | benign(0.053) | TCGA-E2-A1B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Adriamycin | SD | |
| HSF1 | SNV | Missense_Mutation | rs377258216 | c.1051N>A | p.Ala351Thr | p.A351T | Q00613 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-EX-A8YF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| HSF1 | SNV | Missense_Mutation | c.582N>G | p.Ile194Met | p.I194M | Q00613 | protein_coding | deleterious(0.02) | possibly_damaging(0.779) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| HSF1 | SNV | Missense_Mutation | rs782078876 | c.1409C>T | p.Ala470Val | p.A470V | Q00613 | protein_coding | deleterious(0.02) | probably_damaging(0.962) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HSF1 | SNV | Missense_Mutation | c.1259N>T | p.Pro420Leu | p.P420L | Q00613 | protein_coding | deleterious(0.03) | possibly_damaging(0.851) | TCGA-CM-6165-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HSF1 | SNV | Missense_Mutation | c.257N>G | p.Gln86Arg | p.Q86R | Q00613 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3297 | HSF1 | TRANSCRIPTION FACTOR, DNA REPAIR | QUERCETIN | QUERCETIN | 19296652 | |
| 3297 | HSF1 | TRANSCRIPTION FACTOR, DNA REPAIR | CYCLOHEXIMIDE | CYCLOHEXIMIDE | ||
| 3297 | HSF1 | TRANSCRIPTION FACTOR, DNA REPAIR | BIMOCLOMOL | BIMOCLOMOL | ||
| 3297 | HSF1 | TRANSCRIPTION FACTOR, DNA REPAIR | HSP70 | 9499401,9822662 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |